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SUMMARY
Testicular cancer is the most common cancer in white males between the ages of 15 and 45 years. Treatment may
include the administration of chemotherapy which has been associated with changes in emotional distress, quality of
life, and symptom distress in other cancers. The current study was designed to evaluate the course of these constructs
in a sample of testicular cancer patients undergoing chemotherapy. Patients completed measures of emotional
distress and quality of life prior to, during, and after chemotherapy, with symptom distress measured during
chemotherapy. Thirty percent of patients reported moderate to high levels of distress at pre-treatment baseline that
was associated with worse quality of life. Initial anxiety and distress decreased and stayed low through
chemotherapy and post-treatment follow-up. There were no significant changes in fatigue, nausea or change in
appearance during chemotherapy. The results suggest that some patients evidence pre-treatment anxiety and distress
that appears to be primarily anticipatory, decreases over the course of chemotherapy, and occurs in the context
of improved quality of life and reduced symptom severity. Deleterious changes in emotional distress, quality of life,
and symptom distress seen in other cancer populations were not apparent in our sample of testicular cancer
patients. Copyright # 2003 John Wiley & Sons, Ltd.
INTRODUCTION
Testicular cancer is the most common cancer in
white males between the ages of 15 and 45 years,
accounting for almost a quarter of the cancers in
that age group. The 5-year survival rates for both
stage 1 and 2A/B seminomatous and nonsemino-
matous testicular germ cell tumors (NSGCTT) are
extremely high, averaging between 90 and 100%
(Heidenreich and Hofmann, 1999). 5-year survival
rates for patients with advanced lymph node
involvement are greater than 80%, and the
majority of patients with metastatic disease are
cured using chemotherapy. In addition to the
increased survival afforded by treatments over the
last decade, refinements in techniques and thera-
pies have reduced the iatrogenic effects (e.g.
retrograde ejaculation, severe nausea) which ac-
companied earlier treatments for this disease. This
is particularly true for chemotherapy where the
development of newer antiemetics have allowed
patients to receive therapy in the outpatient
setting.
Chemotherapy frequently starts shortly follow-
ing the initial orchiectomy, with one study
reporting that 90% of patients start chemotherapy
within 2 months post-orchiectomy. Current
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chemotherapy protocols use combinations of
bleomycin, etoposide, and cisplatin (the BEP
regimen) (Brada et al., 1987; Dearnaley et al.,
1991; Williams and Einhorn, 1982). For indivi-
duals with NSGCTT, three courses of BEP are
usually sufficient, with the cycles repeated every 21
days (Cullen et al., 1996).
While it frequently increases survival rates,
chemotherapy in cancer patients has been
found to exert significant physical effects as
well. Common physical side effects during
the course of treatment include nausea and
vomiting, alopecia, fatigue, anorexia, mouth and
gastric ulceration, diarrhea, neuropathy, and
sexual problems (e.g. sterility, decreased desire)
(Golden et al., 1980; Penman et al., 1984).
In addition, chemotherapy often results in depres-
sion, anger, and anxiety (Arai et al., 1996;
Freidenbergs et al., 1980; Meyerowitz, 1980).
In some patients, nausea and anxiety occur prior
to in addition to following chemotherapy
(Bovbjerg et al., 1990; Nesse et al., 1980; Redd
et al., 1982; van Komen and Redd 1985). Given
the potential side effects, it is possible that
chemotherapy may increase emotional distress
and decrease quality of life.
Surprisingly, more extensive investigations into
changes in emotional distress and quality of life
have not been conducted with testicular cancer
patients. The majority of studies that have been
conducted have focused on psychosocial variables
following the completion of treatment and not
changes that occur during treatment. Moreover,
most of these studies have been retrospective in
nature. Few, if any, have included pre-treatment
baseline and follow-up assessments. Studies eval-
uating distress in cancer patients throughout the
course of chemotherapy have found that antici-
patory anxiety is higher before the first chemother-
apy cycle, and state anxiety is related to the
presence of somatic side effects (e.g. post-treat-
ment nausea) (Andrykowski et al., 1985; Jacobsen
et al., 1993). Thus far, however, studies have
focused on other forms of cancer (e.g. breast,
ovarian) and have not investigated the effects of
chemotherapy in testicular cancer. As such, the
purpose of this pilot study was to: (1) identify the
course of emotional health and quality of life in
testicular cancer patients before, during, and after
chemotherapy, and (2) assess the degree of
symptom distress in patients during the course of
chemotherapy. It was hypothesized that emotional
distress/anxiety would be higher at the start
of chemotherapy, that symptom distress would
increase and be correlated with emotional distress
over the course of chemotherapy, and emotional




Between January 1999 and June 2001, 16 males
scheduled to begin chemotherapy for testis cancer
who were over the age of 18 years of age were
approached, with all agreeing to participate in this
pilot study. All patients provided written informed
consent. The study and consent form were
reviewed and approved by the University of
Michigan Institutional Review Board. Patients
ranged in age from 20 to 47 years (X=31.25,
S.D.=8.95). Table 1 presents the demographic
data, stage of disease, and histopathological type
for all patients.
Chemotherapy
Individuals on average underwent 3 cycles of
chemotherapy with the BEP regimen over a span
of 9 weeks on an outpatient basis at the University
of Michigan Comprehensive Cancer Center. The
cycles included daily treatment during the first
week, and then treatment once/week for the next
two weeks, with the cycle repeating itself on
the 22nd and 44th day. Treatment was provided
by a team of medical professionals led by two
physicians, a nurse practitioner and a physician
assistant. Chemotherapy was delivered in the
outpatient infusion area of the University of
Michigan Comprehensive Cancer Center by che-
motherapy certified nurses. Subjects received a
standard antiemetic regimen consisting of a 5-HT3
receptor antagonist (granisetron or ondansetron)
and dexamethasone. Prochlorperazine, thiethyl-
perazine and lorazepam were used on an as needed
basis.
Instruments
Brief Symptom Inventory (BSI): The BSI
is a 53-item measure of emotional distress
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which takes between 5 and 10min to com-
plete (Derogatis, 1992; Derogatis and Melisaratos,
1983). It has well-demonstrated reliability
and validity (Boulet and Boss, 1991). Individual
items are answered on a ‘0’ (not at all distressed)
to ‘4’ (extremely distressed) scale and are summed
into one of the nine clinical scales and
three summary scales. One of these, the Gene-
ral Severity Index (GSI), provides a sensitive
measure of overall distress. The BSI is standar-
dized using area t-scores, each with a mean of 50
and a standard deviation of 10. Area t-scores
>1 S.D., above the mean have been identified as
representative of moderate to clinically significant
distress.
Functional Assessment of Cancer Treatment-
General (FACT-G): The FACT-G is a 47-item
questionnaire assessing quality of life (Cella et al.,
1993; Cella, 1994). It is composed of five scales:
physical well-being social/family well-being
emotional well-being functional well being, and
relationship with doctor. It has demonstrated
reliability and validity. Lower scores on the
FACT-G represent poorer QOL.
Symptom Distress Scale (SDS): The SDS is a
10-item 5-point scale that asks patients to rate the
number that best corresponds to physical feelings
(e.g. feeling sick, tired, bowel problems, appear-
ance) commonly felt in response to chemotherapy
‘during the past week including today’. Each item
ranges from ‘1}no problems’ to 65}the worst
possible problems’ in each area. Items can be
totaled to obtain an overall symptom distress
scale, with higher scores indicating more distress.
The reliability coefficient alpha has been reported
as 0.821 with the standardized item alpha reported
as 0.5826 indicating food reliability (McCorkle
and Young, 1978).
Procedure
After providing consent, all participants
completed written self-report questionnaires
timed to coincide with regular clinic visits. Patients
completed a pre-treatment baseline questionnaire
package that included a demographic question-
naire, the BSI, and the FACT-G. On the first
day of each treatment cycle, patients completed
the BSI, FACT-G, and SDS, before pre-medica-
tion for chemotherapy. Subsequently completion
of the BSI and FACT-G occurred during
clinic follow-up visits 3- and 8-months after
patients completed chemotherapy. As such pa-
tients completed six assessments over the course of
the study.
Statistical analyses were performed using SPSS
10.0 (Chicago, IL). Associations between contin-
uous variables were computed using Pearson’s
product moment correlation coefficient. Long-
itudinal comparisons of measures from baseline
through chemotherapy were computed using
repeated measures analysis of variance (ANOVA).
Comparisons of scores on measures following the
last chemotherapy with 3- and 8-month follow-up
utilized paired t-tests.






Time since orchiectomy (months) 1–13 (2)




Resected, no residual 1 (6.2)
Small volume 12 (75)
















High school graduate 6 (37.5)
Some college 4 (25)
College graduate 3 (18.8)
Professional/graduate school 3 (18.8)
Employment
Employed for hourly wages 9 (56.3)
Self-employed 2 (12.5)
Student 2 (12.5)
Medically disabled 1 (6.3)
Other 2 (12.5)
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RESULTS
Baseline distress and quality of life
As a group, individuals with testicular cancer
did not demonstrate significantly increased mean
levels of distress or significantly lower mean
quality of life ratings compared with published
normative data on the BSI and FACT-G. There
was, however, considerable variability in these res-
ponses. Approximately 30% (5/16) of the sample
reported scores greater than 60 on the GSI scale.
Moreover, GSI scores were negatively correlated
with the social/family well-being (r=0.68,
p50.01) and emotional well-being (r=0.56,
p50.05) scales of the FACT-G, along with the
FACT-G total score (r =0.54, p50.05). Similar
results were observed for the Depression, Hosti-
lity, and Somatization scales of the BSI (all
p5 0.05).
Distress and quality of life during and after
chemotherapy
The results of the repeated measures ANOVAs
on distress and quality of life during the course of
chemotherapy revealed significant decreases in the
overall level of distress as measured by the GSI,
F (3, 12)=4.69, p=0.02, and the Anxiety subscale,
F (3, 12)=4.00, p=0.03, of the BSI. Observed
power to detect differences in both cases exceeded
0.70. In both cases, distress decreased from base-
line to the end of three cycles of chemotherapy. No
differences were observed on the GSI and Anxiety
scales at 3- and 8-month follow-up when com-
pared with the levels observed at the end of
chemotherapy.
In contrast, to the course of distress, the
physical well-being scale of the FACT-G did
not show significant changes from baseline
over the course of chemotherapy, F(3, 13)=2.61,
p=0.09, ns. This primarily appears to be the
result of low power to detect change (0.51).
Consistent with the aforementioned findings for
the GSI and Anxiety scales of the BSI, the
emotional well-being scale of the FACT-G
revealed a significant increase in quality of life
from baseline over the course of chemotherapy.
F(3, 13)=8.67, p=0.002. No differences were
observed on the FACT-G emotional well-being
scale when the post-third round chemotherapy
score was compared with the 3- and 8-month
follow-up scores using paired t-tests. As would be
expected, significant improvements were observed
in the FACT-G Physical Well-being scale when
post-third round chemotherapy score was com-
pared with 3 and 8 month follow-up scores,
t(11)=3.21, p=0.008 and t(10)=4.01, p=0.002,
respectively. Table 2 presents the means and
standard deviations for the BSI and FACT-G
scales.
Symptom severity over the course of chemotherapy
An examination of the severity of symptoms
experienced by individuals as measured by the
SDS revealed that overall, patients reported very
low levels of problems such as feeling sick, poor
appetite, pain, appearance, fatigue, and sleep
over the course of chemotherapy. SDS Total score
did not change significantly over the course of
chemotherapy, F (2, 14)=1.36, p=0.029, ns. That
said, over the three cycles of chemotherapy, those
areas that were reported to be the most disrupted
were fatigue, sleep, mood and appetite. In each
case, the greatest disruption in these areas
occurred after the second round of chemotherapy,
with a reduction by the end of the third round.
Correlations between the SDS total score and
the GSI at each assessment during chemo-
therapy revealed significant correlations after
the first (r=0.668, p=0.006) and second
(r=0.608, p=0.013), but not after the third round
(r=0.0285, p=424). This is somewhat expected
given the number of physical complaints included
in the GSI.
DISCUSSION
Within the last few decades, research into the
various combinations of chemotherapeutic agents
has significantly increased the ability to success-
fully treat testicular cancer. In addition, refine-
ments in the administration of these agents have
reduced that short- and long-term side effects (e.g.
nausea and vomiting) associated with chemother-
apy. Such refinements have led to the increased
relocation of chemotherapy administration
form inpatient to outpatient settings. The impact
of outpatient administration of chemotherapy
on testicular cancer patients’ emotional distress,
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quality of life, and symptom distress has not yet
been studied. The current study was designed to
examine longitudinally the emotional distress,
quality of life, and symptom distress ratings of
patients before, during, and after three rounds of
chemotherapy.
Consistent with previous research with cancer
patients (Derogatis et al., 1983; Zabora et al.,
2001), results from the current study indicate
that while the majority of testicular cancer patients
have average levels of distress that do not
differ from a healthy population (Derogatis, 1992),
a sizeable proportion (approximately 30% in
the current sample) exhibit significantly higher
levels of distress at pre-treatment baseline.
This proportion is consistent with the majority of
reports examining distress in cancer patients
(Derogatis et al., 1983; Farber et al., 1984; Trask
et al., 2001; Stefanek et al., 1987). In addition,
increasing distress was associated with lower
social/family well-being and lower levels of emo-
tional well-being. Psychologists or other mental
health care professionals may be of benefit to those
individuals who report levels of distress and
reductions in QOL exceeding pre-identified
cutoffs.
Of greater interest is the finding that distress was
accompanied by increased levels of anxiety at
baseline, but that both decreased over the course
of chemotherapy, a finding consistent with finding
by Jacobsen et al. (1993). We suggest that this
represents anticipatory anxiety and distress that is
likely the result of individuals fearing what they
may experience as a result of chemotherapy; levels
that decrease once individuals start treatment.
This observation is supported by the overall lack
of problems in such areas as nausea, fatigue, sleep,
and appearance reported by patients during their
chemotherapy. Over the course of chemotherapy,
minimal symptom distress was reported. As noted
by the increase and subsequent decrease in
symptom distress following the second and third
rounds of chemotherapy, respectively, it appears
that any symptom distress that became present
was successfully addressed with antiemetics with
minimal emotional distress associated with it.
Moreover, the decreases in emotional distress
and improvements in quality of life observed
Table 2. Means (S.D.) for BSI and FACT-G scales prior to, during, and after chemotherapy
Variable Baseline Post Post Post 3-month 8-month
1-month 2-month 3-month follow-up follow-up
Brief Symptom Inventory (BSI)
Somatization 54.07 55.67 59.12 52.00 48.00 51.27
(10.42) (6.83) (5.00) (8.77) (9.52) (8.76)
Depression 54.53 53.33 52.25 51.30 48.67 52.73
(10.08) (9.05) (9.25) (9.55) (6.08) (10.42)
Anxiety 58.13 52.53 48.37 50.50 45.33 51.64
(11.17) (9.28) (7.79) (10.38) (7.08) (13.40)
Hostility 54.27 52.13 54.31 52.00 47.92 50.55
(11.08) (9.41) (8.57) (9.46) (9.02) (10.60)
GSI 54.67 52.73 53.25 50.80 46.25 49.27
(12.36) (9.79) (8.64) (9.48) (9.51) (13.65)
Functional Assessment of Cancer
Therapy-General (FACT-G)
Physical well-being 25.12 24.16 21.37 24.10 26.42 26.36
(3.28) (3.14) (5.49) (2.56) (3.37) (1.96)
Social/family well-being 24.09 24.04 24.91 24.70 25.84 25.50
(3.82) (3.85) (3.26) (1.57) (2.25) (3.47)
Emotional well-being 14.75 16.81 17.62 17.40 18.33 22.91
(2.84) (3.12) (2.42) (3.24) (1.72) (19.15)
Functional well-being 18.86 20.31 18.73 21.50 24.00 22.91
(6.01) (4.76) (5.53) (3.31) (5.36) (4.55)
Total FACT-G 90.15 92.77 89.32 94.60 102.01 99.95
(12.64) (11.22) (14.96) (8.21) (9.73) (10.64)
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during chemotherapy continued up to the 8-month
follow-up. For oncologists and others on the
health care team, these results suggests that
additional education efforts conducted prior to
chemotherapy on the likely course of treatment
and side effects may reduce anxiety in testicular
cancer patients.
Several caveats should be noted. First, the study
did not include either a control population of
healthy subjects or a comparison group of either a
different population of cancer patients receiving
chemotherapy or a group of testicular cancer
patients receiving a different treatment. As such,
no direct comparisons can be made within this
study. Despite this, however, the results of the
current study, in both the average ratings of
distress and ‘caseness’ (i.e. proportion of distressed
participants), are consistent with those reported
for other cancer patients (Derogatis et al., 1983;
Zabora et al., 2001; Stefanek et al., 1987). A
second caveat is the fact that because the results of
the current study are longitudinal, there is greater
opportunity for missing data. As an example,
although 16 patients provided baseline informa-
tion, only 10 patients provided data at every time-
point through the 8 month follow-up. This
attrition, in addition to the fact that only 16
patients were accrued over a two-year period,
argues for the need for multi-site studies that will
allow for increased accrual and increased efforts to
obtain data from participants throughout the
study period. A third limitation is the limited
sample size. Initial power calculations for this
study suggested that in order to detect a 20%
reduction using the GSI subscale during the course
of chemotherapy with 90% power with a type 1
error of 5%, 81 patients would be required.
During the pilot study, 51–82% power was
expected for the types of comparisons being
performed. The lack of power was observed in
several calculations, although exceeded 70% in at
least one. Nevertheless, it points to the need
for a larger study that utilizes several collection
sites to obtain the number of patients needed in a
reasonable amount of time. Finally, the fact that
only one clinic was utilized further limits the
potential generalizability of the results. Further
studies using both community hospitals and large
medical centers would provide additional informa-
tion as to whether the limited symptom distress
reported in this study was a function of the setting.
Despite the limited sample size, the results from
the current study identify several important points
for further exploration. The first is that individuals
frequently display anticipatory anxiety prior to
starting chemotherapy. Although not explored in
the current study, it will be important for future
studies to determine whether this has an effect on
variables such as decision-making or involvement
with treatment. The second is that this study
presents, to our knowledge, the first assessment
of emotional and symptom distress, and quality
of life longitudinally through the course of
chemotherapy. While larger samples are clearly
needed before making firm conclusions, the
tentative interpretation is that social and emo-
tional distress is not increased during chemother-
apy in testis cancer patients being treated on an
outpatient basis at a University Medical Center,
Longer term evaluations are necessary to deter-
mine if the adjustment seen during treatment
is maintained in the years following treatment
when some of the longer term side effects of
chemotherapy may occur.
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